SCHEMBL16178593

SCHEMBL16178593

Cc1ccc(N2CCNC(CO)C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 8/20 0.54
USP25 Q9UHP3 2/20 0.45
USP28 Q96RU2 1/20 0.45
ESRRB O95718 2/20 0.42
ESRRG P62508 2/20 0.42
KCNH2 Q12809 1/20 0.41
SUV39H2 Q9H5I1 2/20 0.41
ADRA2A P08913 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
SCN9A Q15858 1/20 0.39
WEE1 P30291 1/20 0.39
HTR1A P08908 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
HTR7 P34969 1/20 0.38
HTR2B P41595 1/20 0.38
HTR5A P47898 1/20 0.38
HTR6 P50406 1/20 0.38
CDK4 P11802 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24028130 0.86 ADRB1 (0.46) ADRB1USP25USP28ESRRBESRRG
SCHEMBL29104004 0.84 ADRB1 (0.45) ADRB1USP25USP28ESRRBESRRG
SCHEMBL21876742 0.84 LTA4H (0.46) ADRB1USP25USP28SUV39H2ADRA2A
SCHEMBL29104008 0.84 ADRB1 (0.45) ADRB1USP25USP28ESRRBESRRG
SCHEMBL29104071 0.84 ADRB1 (0.45) ADRB1USP25USP28ESRRBESRRG
SCHEMBL21876740 0.84 LTA4H (0.46) ADRB1USP25USP28SUV39H2ADRA2A
SCHEMBL6907009 0.84 ADRB1 (0.60) ADRB1USP25USP28KCNH2ADRA2A
SCHEMBL6907013 0.84 ADRB1 (0.60) ADRB1USP25USP28KCNH2ADRA2A
SCHEMBL20883649 0.84 ADRB1 (0.42) ADRB1USP25USP28SUV39H2ADRA2A
SCHEMBL22542075 0.82 ADRB1 (0.47) ADRB1USP25USP28WEE1HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020210377-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF NUVATION BIO INC. (US) 2020-10-15 WO disclosed
WO-2020210383-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF NUVATION BIO INC. (US) 2020-10-15 WO disclosed
US-9096614-B2 Therapeutically active thiazolo-pyrimidine derivatives UCB PHARMA SA (BE) 2015-08-04 US disclosed
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives UCB PHARMA SA (BE) 2014-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives TPMT, IFNG, IRF3 ADRB1 1401/4885USP25 4395/4885USP28 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.